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White adipose tissue (WAT) mass is determined by
adipocyte size and number. While adipocytes are
continuously turned over, the mechanisms control-
ling fat cell number in WAT upon weight changes
are unclear. Herein, prospective studies of human
subcutaneous WAT demonstrate that weight gain in-
creases both adipocyte size and number, but the
latter remains unaltered after weight loss. Transcrip-
tome analyses associate changes in adipocyte num-
ber with the expression of 79 genes. This gene set is
enriched for growth factors, out of which one, trans-
forming growth factor-b3 (TGFb3), stimulates adipo-
cyte progenitor proliferation, resulting in a higher
number of cells undergoing differentiation in vitro.
The relevance of these observations was corrobo-
rated in vivo where Tgfb3+/ mice, in comparison
with wild-type littermates, display lower subcutane-
ous adipocyte progenitor proliferation, WAT hyper-
trophy, and glucose intolerance. TGFb3 is therefore
a regulator of subcutaneous adipocyte number and
may link WAT morphology to glucose metabolism.
INTRODUCTION
White adipose tissue (WAT)mass is determined by its cellularity—
in other words, the size and number of adipocytes. Cross-
sectional analyses in adult human WAT have shown that both
measures are markedly higher in obesity, albeit to a variable de-
gree (Hirsch and Batchelor, 1976). The relation between fat mass
and fat cell size is modeled by an asymptotic curve (Spalding
et al., 2008), which reflects the fact that human adipocytes canCell
This is an open access article under the CC BY-Nonly attain a maximum volume of 2,000 pL. This has resulted in
the hypothesis that WAT expansion depends on both increased
fat cell size (hypertrophy) and number (hyperplasia) (Hirsch and
Batchelor, 1976; Spalding et al., 2008), processes that may be of
pathophysiological relevance. Thus, while WAT hypertrophy is
associatedwith insulin resistance and increased risk of type 2 dia-
betes, hyperplasia is protective (Arner et al., 2011; Weyer et al.,
2000) and is dependent on the proliferation and differentiation of
adipocyte precursors present in the stromal-vascular fraction
(SVF) of WAT. However, the relative contribution of either expan-
sion mode under hypercaloric conditions has been debated. An
older overfeeding study, which resulted in a 21% body weight in-
crease in 6months, concluded thatWAT grew primarily via hyper-
trophy (Salans et al., 1971). In contrast, data from an 8-week-long
study (7% increase in body weight) in normal-weight individuals
suggested that abdominal subcutaneous WAT (sWAT) expanded
primarily viahypertrophy,while femoral sWAT increasedviahyper-
plasia (Tchoukalova et al., 2010). Other reports have not been able
to detect changes in fat cell size (Alligier et al., 2012; Samocha-
Bonet et al., 2010) or number (Alligier et al., 2012), but these inter-
ventions resulted only in modest body weight increases (3%–4%)
and were relatively short (28–56 days). Because the annual turn-
over of adipocytes in adult humans is 10% (Spalding et al.,
2008), it is possible that short-term interventions may not result
in detectable changes in WAT cellularity. In a long-term study,
we recently demonstrated that subcutaneous abdominal fat cell
number increased in obese subjects who regained weight be-
tween 2 and 5 years after bariatric surgery (Hoffstedt et al.,
2017). This resulted in hyperplastic sWAT and a healthier meta-
bolic phenotype compared with body weight-matched never-
obese controls. Human sWAT may expand via both hypertrophy
and hyperplasia, and the relative contribution of eithermechanism
can be of relevance in relation to metabolic phenotype.
Subcutaneous adipocyte number increases during adoles-
cence, plateaus in early adulthood among weight-stableReports 25, 551–560, October 16, 2018 ª 2018 The Author(s). 551
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
individuals (Spalding et al., 2008), and is doubled in obese sub-
jects compared with non-obese individuals (Spalding et al.,
2008). However, WAT mass loss, whether voluntary (Spalding
et al., 2008) or involuntary (Ryde´n et al., 2008), significantly re-
duces adipocyte volume, whereas fat cell number remains unal-
tered. From this follows that obese subjects who have attained a
non-obese state (termed ‘‘post-obese’’) display WAT hyperpla-
sia in comparison with weight-matched never-obese individuals
(Lo¨fgren et al., 2005). Thus, increases in WAT mass appear to
generate a new set point for adipocyte number that remains un-
altered by long-term weight loss and may be protective against
metabolic complications upon weight regain (Hoffstedt et al.,
2017). This suggests that specific mechanisms operate within
WAT to increase fat cell production during weight gain andmain-
tain elevated adipocyte numbers in adults after weight reduction.
Nevertheless, the endogenous factors controlling fat cell number
have remained unknown.
Morphometric results in human WAT can be compared with
data obtained in animal models. Thus, using different cell-
tracking techniques, studies in male mice have demonstrated
that diet-induced obesity stimulates both hypertrophic and hy-
perplastic expansion of epididymal WAT (often defined as
‘‘visceral’’ [vWAT]), while inguinal WAT (often defined as ‘‘subcu-
taneous,’’ sWAT) only grows via hypertrophy (Jeffery et al., 2015;
Wang et al., 2013b). This notion was recently made more com-
plex by findings demonstrating that sWAT of female mice display
both hypertrophic and hyperplastic expansion (Jeffery et al.,
2016). In the same study, these gender-related differences
were shown to depend on the microenvironment and not on
intrinsic differences between adipocyte precursors. All of this
suggests that murine WAT displays depot- and gender-specific
differences in expansion upon diet-induced obesity. While there
may be qualitative differences in these processes between mice
and humans, it is still valid to determine the impact of specific
genes in murine models.
To identify regulators controlling fat cell number upon
changes in WAT mass, we adopted a translational approach
by combining clinical prospective studies with experimental
models. This resulted in the identification of transforming growth
factor-b3 (TGFb3), a secreted protein expressed in the SVF of
sWAT, which stimulates adipocyte precursor proliferation and
regulates fat cell number in vitro and in vivo.
RESULTS
The Relation between Body Weight Changes and WAT
Cellularity
To monitor cellularity alterations over time, we studied two co-
horts of women from whom repeated abdominal sWAT biopsies
were obtained. Cohort 1 (Table S1) consisted of 27 women from
a previous study examining the long-term effects of weight
changes (mean follow-up of 10 years) (Andersson et al., 2009).
Anthropometric measures, total WAT mass, and mean fat cell
size and number were determined at baseline and follow-up.
The group was divided into tertiles based on spontaneous
changes in body weight over time. In contrast to weight-stable
subjects, individuals who markedly gained weight (on average
18%, range 9%–27%) displayed a significant increase in body552 Cell Reports 25, 551–560, October 16, 2018fat mass, subcutaneous fat cell volume, and total adipocyte
number (Figures 1A–1C). Changes in sWAT cellularity following
pronounced weight loss were determined in a second group of
individuals (cohort 2; Table S2), which consisted of 21 severely
obese women who had reached a non-obese (i.e., post-obese)
state (BMI <30 kg/m2) 2 years after bariatric surgery. Results
were compared with samples obtained from age-, BMI-, and
body fat mass-matched control women who had never been
obese (cohort 3, detailed together with cohort 2 in Table S2).
The number of subcutaneous adipocytes in the post-obese sub-
jects was unaltered despite pronounced WAT mass loss and
therefore significantly higher than that in never-obese controls
(Figures 1D–1F).
To address whether weight gain achieved during different pe-
riods of life could affect WAT cellularity, the 21 obese women in
cohort 2 were subdivided according to whether they had been
overweight (BMIR25kg/m2)before (n=11)orafter (n=10)18years
of age. Total WAT and subcutaneous adipocyte size and number
were similar between the two groups, both before and after
weight loss, suggesting that early or late onset of excess weight
gain does not affect any of the studied parameters (Table S2).
Genes Linked to Subcutaneous Fat Cell Number Are
Enriched for Growth Factors
Weight gain induces significant alterations in the expression of
WAT genes involved in, for example, inflammation, extracellular
matrix formation, lipidmetabolism, and insulin signaling. Virtually
all of these pathways are normalized upon weight loss (Rosen
and Spiegelman, 2014). To identify factors potentially regulating
adipocyte number, we reasoned that the corresponding gene
subset would fulfill the following criteria: (1) altered in obesity,
(2) unaltered by weight loss, and (3) significantly different be-
tween the post-obese and never-obese state, thereby mirroring
the differences in fat cell number in these conditions. Microarray
analyses of sWAT from cohorts 2 and 3 confirmed that the global
transcriptional profile in obesity was normalized by weight loss
(Figure 1G; Table S3) and was overrepresented by pathways
belonging to inflammation, extracellular matrix components,
and lipid metabolism (Table S4). However, 91 probe sets (Fig-
ure 1H), corresponding to 79 unique genes, were altered in
obesity and remained dysregulated in the post-obese state
(i.e., not normalized by weight loss). Pathway analyses revealed
an overrepresentation of genes encoding proteins present in the
extracellular compartment as well as growth factors (GFs),
including TGFB3, chemokine (C-X-C motif) ligand 12 (CXCL12),
fibroblast GF 7 (FGF7), osteoglycin (OGN), and platelet-derived
GF D (PDGFD) (Figure 1I). To determine whether any of the 79
genes were affected by short-term weight gain, their expression
in sWAT was extracted from a previously published study (Alli-
gier et al., 2012). This retrospective analysis identified 12 genes
to be significantly altered by overfeeding, four of which (TGFB3,
CXCL12, OGN, and PDGFD) were among the GFs identified in
the present study.
TGFb3 Stimulates Adipocyte Precursor Proliferation
and Fat Cell Number In Vitro
Fat cells are continuously generated from proliferating precursor
cells in the SVFs of WAT. Because our analyses demonstrated
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Figure 1. Effects of Weight Alterations on
White Adipose Tissue Cellularity and Gene
Expression
(A–C) Subjects in cohort 1 were subdivided into
weight stable and weight gainers. Differences in
body fat mass (A), adipocyte volume (B), and
number (C) are shown. Black bars are at baseline
and white bars are at 10-year follow-up.
(D–F) The same parameters (body fat mass in D,
adipocyte volume in E, and adipocyte number in F)
are displayed for cohorts 2 and 3 comprising
obese subjects before and after bariatric surgery
(bBS and aBS, respectively, white bars) and
never-obese matched controls (Ctrl, gray bars).
(G) Principal-component analysis based on highly
expressed transcripts in subcutaneous abdominal
white adipose tissue from cohorts 2 and 3. Groups
are separated with 95% confidence intervals if
the circles are not overlapping each other. The
contribution of each principal component is indi-
cated as a percentage.
(H) Venn diagram displaying significantly altered
probe sets comparing obese before bariatric sur-
gery with never-obese controls (bBS versus Ctrl),
obese before and after bariatric surgery (bBS
versus aBS), and post-obese with never-obese
controls (aBS versus Ctrl).
(I) Enriched pathways among the 91 probe sets
(corresponding to 79 unique genes) altered in
obesity, not normalized by weight loss, and still
perturbed in the post-obese state. Only the genes
present in at least two pathways are displayed.
Student’s t tests were used to evaluate the results,
and statistical differences are indicated as *p <
0.05, **p < 0.01, and ***p < 0.001. Error bars in
(A)–(F) are SEM.that specific GFs were increased upon short-term weight gain
and were overrepresented among genes linked to fat cell num-
ber in post-obese subjects, further studies were focused on
these factors. Analyses of mRNA expression in intact or fraction-
ated human sWAT revealed that the corresponding GF genes
were primarily expressed in the SVF and only to a limited degree
in mature adipocytes (Figure S1A). Furthermore, microarray data
from fractionated SVFs (Acosta et al., 2017) showed that all GFs
were primarily expressed in the adipocyte progenitor (CD45/
CD34+/CD31) cell fraction (graphs not shown). These findings
were confirmed at the protein level for four of the factors.
CXCL12, FGF7, OGN, and TGFb3 were secreted by undifferen-
tiated human subcutaneous adipocyte precursor cells in vitro,
and the levels were reduced during adipogenesis (Figure S1B).Cell RPDGFD was excluded from further
studies because it could not be detected
using various commercial ELISA kits. The
proliferative effect of each recombinant
protein was assessed in human adi-
pose-derived stem cells (hASCs). This re-
vealed that only one, TGFb3, stimulated
proliferation (measured as cell density
by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphe-
nyltetrazolium bromide [MTT] assay) in aconcentration-dependent manner (Figure 2A). Similar results
were observed in 3T3-L1 cells and primary murine adipose
SVF cells (graphs not shown). In proliferating hASCs, TGFB3
knock down by RNAi resulted in a marked downregulation of
its mRNA expression (Figure 2B). This caused attenuated cell
proliferation, which could be rescued by incubation with
increasing concentrations of recombinant TGFb3 (Figure 2C).
The link between TGFb3 and fat cell number was further sub-
stantiated by the observation that incubation with recombinant
TGFb3 followed by induction of adipocyte differentiation resulted
in a significant increase in the formation of adipocytes (Fig-
ures 2D and 2E). This was achieved without affecting adipogen-
esis per se, as the expression of classical white adipocyte
markers (ADIPOQ, PPARG, and PLIN1) was not affected ineports 25, 551–560, October 16, 2018 553
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Figure 2. Effects of TGFb3 in Human Adipocytes In Vitro
(A) Proliferative effects of recombinant CXCL12 (1–50 ng/mL), OGN (1–100 ng/mL), FGF7 (1–50 ng/mL), or TGFb3 (1–100 ng/mL) in in vitro cultured human
adipose-derived stem cells (hASCs). Cell density was determined by MTT as described in the STAR Methods and expressed as fold change versus cells
incubated in control medium.
(B andC) hASCswere transfectedwith TGFB3 or non-silencing small interfering RNA (siRNA) oligonucleotides. This resulted in a significant knock down of TGFB3
mRNA expression (B). It also induced a significant attenuation of cell density or number determined by MTT, an effect that was rescued in a concentration-
dependent manner by recombinant TGFb3 protein (C).
(D and E) hASCs were first incubated with 10 ng/mL recombinant TGFb3 for 72 hr. After removal of TGFb3 for an additional 72 hr, adipogenesis was induced as
described in the STAR Methods. Triglyceride accumulation at terminal differentiation was determined by oil red O staining (D) and quantified using ImageJ (E).
(F) Effects on adipocyte-specific gene expression were determined by qPCR in differentiated cells treated as in (D).
(G) hASCs were incubated with 10 ng/mL TGFb3 for 24 hr. Cells were lysed and RNA analyzed by gene microarray. Bioinformatic analysis identified the top five
upregulated and downregulated pathways, respectively.
In (A), (B), and (E), Student’s t test was used to evaluate the results, and statistical differences are indicated as **p < 0.01 and ***p < 0.001. In (C), ANOVA and post
hoc tests were used to evaluate the results, and statistically significant differences (p < 0.05) between conditions are indicated by connecting letters. Scale bars,
100 mm. Error bars in (A) are SEM, and in (B), (C), and (E)–(F), error bars are SD.TGFb3-incubated compared with control-incubated cells (Fig-
ure 2F). To gain insights into the pathways induced by TGFb3,
hASCs were incubated for 24 hr with recombinant protein. In
concordance with the observed in vitro effects, array analyses
showed that the most significantly downregulated genes were
involved in cell growth and negative regulation of cell prolifera-
tion, while the upregulated ones were involved in extracellular
matrix organization (Figures 2G and S1C).
Unique Regulation of TGFb3 Expression in Relation to
Other TGFb Members in sWAT
TGFb3 belongs to a family of GFs that currently comprises three
members in mammals (TGFb1to -3). Although all three genes
(TGFB1 to -3) display large sequence homologies in their active554 Cell Reports 25, 551–560, October 16, 2018domains, the individual proteins play distinct roles, as evidenced
both by their activation of specific cell-surface receptors and the
phenotypes of isoform-specific knockout mice (Laverty et al.,
2009). Analyses of microarray data in cohorts 2 and 3 revealed
that the expression of both TGFB1 and TGFB3 were higher in
obesity, but that TGFB1, in contrast to TGFB3, was normalized
in the post-obese state; in contrast TGFB2 was not affected by
eitherobesity orweight loss (FigureS1D). Theexpressionpatterns
of TGFB1 to -3 in cohorts 2 and 3 were validated by qPCR (Fig-
ure S1E). We somewhat unexpectedly found that the levels of
TGFB3 in vWAT were lower in obese compared with non-obese
subjects (Figure S1F). This suggests that the link between
increased TGFb3 levels and adipocyte number in obesity is spe-
cific for this TGFbmember and only for the subcutaneous depot.
A B
Wt KO
0
1
2
3
4
Li
pi
d
ar
ea
( %
)
C
Wt KO
***
0
10
20
30
40
50
60
Wt KO
E
dU
po
si
tiv
e
ce
lls
(%
)
*
0
5
10
15
20
25
30
35
40
45
E
dU
po
si
tiv
e 
ce
lls
(%
)
***
D EHoescht EdU Merged
Tgfb3+/+
Tgfb3+/- Tgfb3+/+ Tgfb3+/-
Tgfb3 HFD
Figure 3. Effects of Tgfb3 Depletion in Murine Cells
(A) Proliferation capacity of murine embryonic fibroblasts (MEFs) derived from Tgfb3+/+ (WT) and Tgfb3/ (KO) mice determined by EdU incorporation.
(B and C) Adipogenic differentiation of WT and KO MEFs was determined by oil red O staining (B) and triglyceride accumulation quantified using ImageJ (C).
(D) Primary cells from the stroma vascular fraction of Tgfb3+/+ or Tgfb3+/ animals were cultured in the presence of EdU for 24 hr. Cells were stained for nuclei
(Hoescht) and EdU (Alexa Fluor 647), and merged panels are shown at right.
(E) The fraction of EdU-positive cells was determined and quantified using ImageJ. ***p < 0.001, *p < 0.05. Scale bars, 100 mm. Error bars in (A), (C), and (E) are SD.Expression of TGFB Members and Their Receptors in
Cells of Human Subcutaneous Adipose Tissue
Expression analyses of fractionated sWAT confirmed that all
three described TGFb3 receptor genes (TGFBR1, TGFBR2,
and ACVRL1) (Laverty et al., 2009) were present in resident
WAT cells, two of which (TGFBR2 and ACVRL1) were enriched
in adipocyte progenitors (Figure S1G). Further analyses in the
same dataset demonstrated that TGFB2 and -3weremost highly
expressed in progenitor cells, while TGFB1 was particularly
prominent in leukocytes (Figure S1H). Data at the single-cell level
(Acosta et al., 2017) confirmed an enrichment of TGFB3 in
human adipocyte precursor cells (Figure S1I).
Depleted Tgfb3 Expression Reduces Proliferation and
Adipocyte Differentiation In Vitro
To further test the causal link between TGFb3 and WAT
morphology, studies were performed in murine in vitro and
in vivomodels. Mice homozygous for Tgfb3 deletions (Tgfb3/,
knockout [KO]) die shortly after birth due to cleft palate and de-
fects in pulmonary development (Kaartinen et al., 1995; Proetzel
et al., 1995). We therefore initiated our studies by establishingTgfb3+/+ (wild-type [WT]) and Tgfb3/ (KO) murine embryonic fi-
broblasts (MEFs). In comparison with WT, KO MEFs displayed
significantly lower proliferation rates determined by 5-ethynyl-
20-deoxyuridine (EdU) staining (Figure 3A). This resulted in fewer
proliferating adipocyte precursors, as supported by the observa-
tion that adipogenic induction resulted in fewer cells undergoing
adipocyte differentiation (Figures 3B, 3C, and S2A–S2C). qPCR
analyses in MEFs during differentiation confirmed that Tgfb3
was undetectable in Tgfb3/ cells, that there was no compensa-
tory change in the expression of Tgfb1 or -2, and that the expres-
sion of Tgfb receptors was not affected by genotype (Figures
S2D–S2I). In contrast to the findings in hASCs andprimarymurine
adipocytes, as well as 3T3-L1 cells, recombinant Tgfb3 did not
affect the proliferation of KO MEFs (Figure S2J; see also Discus-
sion). The experiments in MEFs were therefore complemented
by analyses in primary SVF cells fromWATofWTor heterozygous
Tgfb3+/ mice. This showed that the proportion of EdU+ prolifer-
ating cells was significantly lower in cells from Tgfb3+/mice (Fig-
ures 3D and 3E). In line with the data in hASCs, this phenotype
could be rescued by recombinant Tgfb3 in SVF from Tgfb3+/ an-
imals (Figure S2K).Cell Reports 25, 551–560, October 16, 2018 555
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Figure 4. Diet-Induced Effects of Tgfb3
Haploinsufficiency
(A) Tgfb3+/+ and Tgfb3+/ male mice were fed
chow (CD) or high-fat diet (HFD) for 11 weeks.
Total body weight was determined weekly.
(B) Pulse-chase experiments were performed by
administering EdU in the drinking water at weeks
4–5 (i.e., during the first week of HFD). After
11 weeks, animals were sacrificed, and inguinal
(subcutaneous white adipose tissue [sWAT]) and
epigonadal (vWAT) depots were obtained. Mature
fat cells were isolated, and the proportion of EdU+
nuclei was determined by fluorescence-activated
cell sorting.
(C) Representative micrographs of sWAT and
vWAT from animals on HFD.
(D and E) For both depots mean adipocyte weight
(D) and number (E) were assessed.
(F and G) Gene expression in sWAT (F) and vWAT
(G) from animals on HFD was determined by
qPCR.
(H and I) Genotype-induced effects on glucose
metabolism were assessed by glucose tolerance
test in animals on HFD (H). Area under the curve
(AUC) was calculated (I).
In (A), ╪ denotes statistically significant difference
between diets. In all of the other panels, *p < 0.05,
**p < 0.01, and ***p < 0.001, using Student’s t test.
Scale bars, 100 mm. Error bars in (A) and (H) are
SEM, and in (F)–(G), error bars are SD.Attenuated Tgfb3 Expression Leads to sWAT
Hypertrophy In Vivo
Given the early lethal phenotype of homozygous Tgfb3 KO ani-
mals, in vivo studies were performed in Tgfb3+/ mice. These
animals do not display any obvious macroscopic phenotype
compared with Tgfb3+/+ littermates. The impact of attenuated
Tgfb3 expression under isocaloric and hypercaloric conditions
was determined by pair feeding male litters regular chow (CD)
or high-fat diet (HFD) for 12 weeks (between weeks 4–16 of
age), respectively. Compared to CD, HFD resulted in amore pro-
nounced body weight increase, but there were no genotype-
dependent differences in the weight attained (Figure 4A). More-
over, food intake (Figure S3A), energy expenditure (Figure S3B),
respiratory exchange ratio (Figure S3C), or non-WAT organ556 Cell Reports 25, 551–560, October 16, 2018weights (Figure S3D) were similar be-
tween genotypes. Tissue weights of
sWAT and vWAT increased on HFD
compared with CD, but there were no
genotype differences (Figure S3D). To
determine whether Tgfb3 knockdown
conferred a reduction in adipocyte
precursor proliferation, we performed
pulse-chase experiments with EdU dur-
ing the first week of HFD (weeks 4–5 of
age). Animals were then sacrificed after
11 additional weeks of HFD, and mature
adipocytes were isolated from both
WAT depots, followed by quantification
of EdU+ adipocyte nuclei. This showedthat Tgfb3+/ animals displayed a significantly lower proportion
of EdU+ cells in sWAT but not in vWAT (Figure 4B). Further ana-
lyses of WAT cellularity measures were performed by deter-
mining adipocyte size and weight in histological sections of the
two depots following CD (Figures S4A and S4B) and HFD (Fig-
ures 4C and 4D). In both genotypes, HFD increased adipocyte
size significantly in sWAT and vWAT. The effect in vWAT was
comparable between genotypes (compare Figures 4D and
S4B). However, in sWAT of Tgfb3+/ animals, fat cell size was
significantly larger, a difference already evident on CD (Figures
S4A and S4B). Thus, Tgfb3+/ mice fed a CD had a fat cell size
that was comparable to that of WT animals on HFD, with subcu-
taneous adipocyte size increasing even further upon HFD (Fig-
ure 4D). In concordance with other studies (see Introduction),
vWATbut not sWATdisplayed an increase in fat cell number upon
HFD (Figures 4E andS4C). Independent of diet, Tgfb3+/ animals
displayed almost 50% fewer subcutaneous fat cells compared
with WT littermates. This confirmed that the Tgfb3+/ animals
were characterized by a significant, depot-specific hypertrophy
in sWAT. qPCR analyses of the WAT depots in animals fed CD
(Figures S4D and S4E) or HFD (Figures 4F and 4G) confirmed
that haploinsufficient mice expressed 50% lower Tgfb3
mRNA levels in both WAT depots. Further expression analyses
were performed on genes related to adipocytes (Pparg and
Adipoq), insulin response (Slc2a4, Irs1, Irs2, and Srebf1), and
inflammation (Ccl2 and Tnfa). While there were no specific differ-
ences between genotypes on CD, several genes were signifi-
cantly (Adipoq, Irs1, and Irs2) or borderline significantly (Pparg
and Slc2a4) lower in the Tgfb3+/ animals. These genes are
known to be downregulated in hypertrophic WAT (Gao et al.,
2014). The effects on gene expression were specific to WAT
because no genotype-related differences were observed in liver
or skeletal muscle (Figures S4F and S4G) in either diet.
sWAT Hypertrophy Associates with Glucose Intolerance
upon High-Fat Diet
To determine whether the differences in WAT cellularity
conferred any metabolic consequences, we performed insulin
tolerance (Figures S4H and S4I) and glucose tolerance tests (Fig-
ures 4H and S4J). As expected, HFDworsened insulin resistance
(Figures S4H and S4I) and induced glucose intolerance
(compare Figure 4H with Figure S4J). However, while there
was no genotype-linked difference in the insulin tolerance tests
(which primarily reflect insulin sensitivity in skeletal muscle),
glucose tolerance tests showed that Tgfb3+/ mice on HFD dis-
played significantly larger glycemic excursions (Figures 4H and
4I). Thus, reduced Tgfb3 expression induced sWAT hypertrophy
and, upon HFD feeding, also glucose intolerance.
DISCUSSION
Several organs have the capacity to increase their size via hy-
pertrophy and/or hyperplasia, resulting in phenotypes that are
retained after pronounced tissue loss. In particular, the term
‘‘skeletal muscle memory‘‘ refers to the observation that mus-
cle fibers that have once been hypertrophic display an
improved capacity to regain mass compared to naive fibers
(Gundersen, 2016). Our long-term prospective data demon-
strate that human WAT expands through a combination of
both increased fat cell size and number but that only the former
is reversed after weight loss. Given that adipocytes are contin-
uously turned over, this indicates a ‘‘hyperplastic’’ memory in
WAT following tissue expansion. In an attempt to clarify mech-
anisms that control the observed changes, we performed tran-
scriptomic profiling to link gene expression to fat cell number.
This enabled us to identify the secreted GF TGFb3, which
accelerated human and murine fat cell formation in vitro. In vivo
studies showed that Tgfb3+/ mice displayed hypertrophic
sWAT, which was associated with impaired glucose meta-
bolism upon HFD. This is in line with clinical studies that primar-
ily link sWAT hypertrophy to impaired glucose metabolism
(Hoffstedt et al., 2010).Our clinical and murine data indicate a depot-specific role for
TGFb3. Thus, while TGFB3 mRNA expression was higher in the
sWAT of obese individuals, the corresponding levels in vWAT
were lower than they were in non-obese subjects. In line with
this, Tgfb3+/ mice displayed pronounced sWAT hypertrophy
under both CD and HFD compared with WT littermates, a finding
that was not observed in vWAT. We admit that the mechanisms
underlying this depot-specificity are not clear but that they may
depend on the well-established regional variations in WAT
phenotype. For instance, both intrinsic differences in the devel-
opmental lineage of adipocyte progenitors (Chau et al., 2014;
Macotela et al., 2012; Sanchez-Gurmaches et al., 2015, 2016)
and extrinsic differences in the microenvironment of the tissue,
including vascularity, cell infiltration, and secretome and meta-
bolic capacity (Jeffery et al., 2016), could explain the differential
role of TGFb3 in determining WAT cellularity. It should be noted
that in contrast to human sWAT, the current consensus is that
male murine sWAT does not display any hyperplasia upon
HFD. Instead, this depot expands via hypertrophic and hyper-
plastic mechanisms between embryonic day (E) 13.5 and pu-
berty (postnatal days 18–34) (Berry et al., 2016; Holtrup et al.,
2017). As reviewed elsewhere (Hepler and Gupta, 2017), murine
studies (Jeffery et al., 2015; Jiang et al., 2014) suggest that
different adipocyte precursors are important for adipogenesis
during development (embryonic and early post-natal) or in
response to HFD. The observation that attenuated Tgfb3 expres-
sion resulted in sWAT hypertrophy under both CD and HFD
therefore suggests that this factor may primarily affect sWAT
expansion in early postnatal stages, but that its role in WAT
mass increase upon hypercaloric diet may differ between
(male) mice and humans. Nevertheless, our combined data in an-
imals and humans suggest that it affects sWAT cellularity. This
does not exclude that other factors may contribute toWAT cellu-
larity via effects on adipocyte precursor proliferation and/or
differentiation (Gao et al., 2014).
Our results in primary human and murine cells suggest that
the mechanisms through which TGFb3 affect sWAT cellularity
involve increased proliferation of adipocyte precursors but no
direct effects on adipogenesis (i.e., the differentiation process)
per se. The reduced adipogenic capacity of KO MEFs but lack
of proliferative response to Tgfb3 could depend on several fac-
tors, including depletion of adipocyte progenitors, differences
in culture conditions, and/or other developmental defects that
alter their response. Nevertheless, MEFs may not be ideal for
these types of studies. It would be important to map Tgfb3-ex-
pressing and -responsive cells to improve our understanding
of its possible (patho)physiological role. Further insights could
be achieved by using more advanced animal models. In partic-
ular, it would be of interest to understand when Tgfb3 is most
important in murine sWAT development, but also to assess the
link between dysregulated expression in adipocyte progenitors
and impaired glucose metabolism. However, although TGFb3
is enriched in adipocyte progenitors (here defined as CD45/
CD34+/CD31), it is also expressed in resident immune cells,
which could also contribute to effects on WAT cellularity. More-
over, our single-cell analyses in adipocyte progenitors did not
identify a specific cell type linked to TGFB3 expression, and at
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specific murine precursors. These considerations, together with
the fact that adipocyte precursor-specific KOmodels have been
difficult to develop (Sanchez-Gurmaches et al., 2016), prompted
us to use a whole-body haploinsufficent animal model.
In human sWAT, TGFB3 was linked to fat cell number in
a manner that was qualitatively different from that of TGFB1
and -2. Furthermore, no compensatory changes in the expres-
sion of these homologs or TGFb3 receptors (Hinck and
O’Connor-McCourt, 2011) were observed upon TGFb3 reduc-
tion (in human and murine cells either in vitro or in vivo). Thus,
our data indicate that TGFb specificity is primarily achieved via
differential expression of TGFbmembers. The factors increasing
TGFB3 in obesity and maintaining the levels in the post-obese
state remain to be defined.
The proposed role of TGFb3 suggested herein is further sup-
ported by a study in mice in which Tgfb3was overexpressed un-
der the Tgfb1 promoter (by replacing the coding sequence of
Tgfb1 with Tgfb3) (Hall et al., 2013). These mice displayed
smaller fat cells upon HFD and improved glucose tolerance.
The clinical relevance of TGFb3 is corroborated by a recent
case report describing a de novo mutation in the TGFB3 gene
(C409Y), which encodes a protein variant (G1226A) that does
not activate its cognate receptors (Rienhoff et al., 2013). This re-
sulted in a complex phenotype that included a pronounced loss
of sWAT. It is therefore conceivable that local TGFb3 administra-
tion could have therapeutic potential in instances in which hyper-
plastic WAT growth is desirable. These instances include invol-
untary weight loss, in which the adipogenic machinery is still
functional (e.g., cancer-related cachexia, age-related cachexia),
and reconstructive surgery (e.g., following mastectomy, severe
burn injuries); in both of these instances, autologous fat trans-
plantation has had poor results (Kølle et al., 2013). The feasibility
of this notion is supported by the fact that TGFb3 has undergone
a clinical development program to improve superficial scar tis-
sue formation under the name avotermin (McCollum et al.,
2011). Hence, local administration of TGFb3 has been shown
to be safe and tolerable in humans. This hypothesis needs to
be tested in experiments in which Tgfb3 is given to animals,
possibly followed by administration of pro-adipogenic stimuli.
A previous study suggested that inhibition of TGFb-signaling
(using a non-selective anti-Tgfb antibody) resulted in increased
thermogenesis via transition of WAT into a brown adipose tis-
sue-like phenotype (Yadav et al., 2011). We observed no differ-
ence in Ucp1 gene expression in white or brown adipose tissue
(data not shown) and no genotype effect on the size of brown
adipose tissue depots. In addition, energy expenditure and res-
piratory exchange ratio (a measure of substrate utilization) was
not different in Tgfb3+/ animals compared with WT littermates.
This suggests that TGFb3 has a specific impact on the WAT
phenotype. The latter notion is also supported by the observa-
tion that there were no genotype-dependent changes in gene
expression in non-adipose tissues, including liver and skeletal
muscle.
Although the clinical biopsies used in the present work were
obtained from the abdominal sWAT of women, and a recent
study in mice suggested that depot-specific WAT expansion is
influenced by gender (Jeffery et al., 2016), there is presently no
evidence in humans that these mechanisms are qualitatively558 Cell Reports 25, 551–560, October 16, 2018different between men and women. However, given that all of
the animals used herein were male, we cannot exclude gender
differences in WAT depot phenotypes between Tgfb3+/ and
WT mice.
Here, we report the identification of a transcriptional finger-
print that is enriched for GFs and linked to sWAT cellularity.
Our in vitro and in vivo analyses suggest that among these
GFs, TGFb3 is involved in hyperplastic sWAT expandability.
This is mediated via effects on adipocyte precursor cell prolifer-
ation, in which weight gain induces an irreversible increase
in TGFb3 that contributes to maintained adipocyte number
following weight loss. Further studies are needed to define
whether this factor may be of clinical relevance in conditions in
which local or general hyperplastic WAT expansion is required.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Subjects
Three cohorts were investigated. Cohort 1 comprised 85 healthy non-obese women recruited 1987-2000 in a study of subcutaneous
adipocytes (Andersson et al., 2009). They were contacted by letter and asked for a re-investigation starting from 1997, which was
before established rules for trial registrations. Thirty-eight women agreed and those who reported either stable or increased body
weight (n = 27) underwent a second adipocyte examination during the period 1998-2007. Cohort 2 consisted of 81 obese women
scheduled for gastric by-pass surgery (Roux-en-Y) between 2006-2009 (Clinical Trial Registration number: NCT01785134) (Ander-
sson et al., 2014). They were post-operatively re-examined at our research unit after two years; 21 had reduced their bodymass index
(BMI) to a non-obese level (< 30 kg/m2), herein defined as a post-obese state. Subjectswere asked for their bodyweight development
during childhood and adolescence as well as their BMI at 18 years of age. Among the 21 post-obese individuals, eleven reported
early- (< 18 years) and ten late- (> 18 years) onset of excess weight gain (BMI > 25 kg/m2). For each post-obese subject, we recruited
a female matched for age and current BMI who had never been obese (Cohort 3). At each time of investigation all subjects were
weight stable (±2 kg) for at least 3 months according to self-report. The study was approved by the regional board on ethics. It
was explained in detail to each participant and written informed consent was obtained.
Animal studies
The generation of the original Tgfb3 KO model has been described previously (Proetzel et al., 1995). Age-matched male C57/BL/6J
Wt (Tgfb3+/+) and Hz (Tgfb3+/) mice (Tudela et al., 2002) (Jackson Laboratories, Bar Harbour, ME) were housed in climate-controlled
quarters with a 12-hour light/dark cycle. Food and water were available ad libitum. Mice were fed either a standard chow diet (13% of
calories derived from fat 2014C, Research Diets; Harlan Laboratories) or a 29% fat diet (Teklad Custom Diet). Animals were handled
following the European Union laws and guidelines for animal care. Experimental procedures were approved by the Universidad Rey
Juan Carlos ethical committee (Madrid, Spain), and special care was taken to minimize animal suffering and to reduce the number of
animals used. Animals were sacrificed by cervical dislocation, total body weight assessed and WAT obtained from subcutaneous
periinguinal (sWAT), perirenal (pWAT) and epidydimal/perigonadal (vWAT) regions. Other tissues (brown adipose tissue, pancreas,
kidney, skeletal muscle and liver) were also dissected. The wet weight of each dissected tissue was measured. Thereafter, one
part was fixed in 4% formalin (pH = 7.0) and used for histological analyses while the remaining specimens were frozen (80C) imme-
diately after removal for subsequent RNA isolation. Determination of adipocyte size was performed exactly as detailed previously
(Gao et al., 2014). In brief, fixed tissues were embedded in paraffin before being sectioned (5 mm) and stained with hematoxylin
and eosin (H & E; Sigma-Aldrich). For each sample, representative photomicrographs were acquired blindly with regard toe2 Cell Reports 25, 551–560.e1–e5, October 16, 2018
genotype/diet from the whole section using the CellInsight CX5 High Content Screening (HCS) Platform (4X magnification). Average
adipocyte size (Feret’s diameter) in each animal was assessed using the ImageJ 1.45 software (National Institutes of Health, Be-
thesda, MD, USA) and the macro MRI’s adipocyte tool. The procedure was performed by two independent operators with similar
results obtained (data not shown). Adipocyte number was calculated by dividing the WAT tissue weight with mean fat cell weight
as described above.
Cell culture
Cultures of hASCs as well as primary cells from the stromal-vascular fraction (SVF) were setup, cultured and differentiated as
described (Gao et al., 2014). In brief, hASCs were obtained from abdominal sWAT of one male donor. Human SVF was obtained
from sWAT of otherwise healthy subjects undergoing cosmetic surgery. In these subjects only BMI, age and gender was known.
All subjects gave informed written consent to donate the tissue and the study is approved by the regional board on ethics. Primary
mouse SVF, 3T3-L1 cells and Murine Embryonic Fibroblasts (MEFs) were handled according to the instructions from American Type
Culture Collection (Manassas, VA). MEFs were cultured in high glucose DMEMcontaining 10%FBS, 2mMglutamine, 0.1mM2-mer-
captoethanol, 50 U/mM penicillin and 50 mg/mL streptomycin. Adipogenesis was induced two days post confluence using DMEM/
F12 Glutamax I containing 10% fetal bovine serum (FBS) supplemented with 5 mg/mL insulin, 0.25 mmol/L dexamethasone,
0.5mmol/L 3-isobutyl-1-methylxanthine (IBMX) and 10 mmol/L rosiglitazone for two days after which the dexamethasone and
IBMX were removed and the cells were allowed to undergo full adipogenic differentiation.
METHOD DETAILS
Clinical examination
After an overnight fast, anthropometric measures (height, weight, waist and hip circumferences) were determined and venous blood
samples were obtained for routine clinical chemistry analyses. Body composition was determined by bioimpendance (Tanita Co,
Tokyo, Japan) for Cohort 1 and by dual-X-ray absorptiometry (GE Luna iDXA, GE Health Care, Madison, WI) for Cohort 2 and 3
as described (Arner et al., 2013). Finally, a sWAT biopsy was obtained from the para-umbilical region by needle aspiration under local
anesthesia.
Determination of human adipocyte size and number
Methods for determination ofWAT cellularity have been described in detail previously (Arner et al., 2013). In brief, isolated adipocytes
were prepared by collagenase incubation. The diameter of 100 cells were determined and shown to be normally distributed. Using
established formulae (Goldrick and McLoughlin, 1970), these values were used to calculate average size and weight of the adipo-
cytes in the WAT biopsy. The precision of the measures is not improved by increasing the number of counted cells (Tchoukalova
et al., 2003) and is comparable to estimating cell size in intact tissue by histology, as discussed previously (Arner et al., 2013).
The total number of adipocytes in the body was determined by dividing body fat mass by mean adipocyte weight. A limitation of
this method is that there are some differences in mean adipocyte volume and weight between fat depots as well as within the sub-
cutaneous depot (Bjo¨rntorp et al., 1975; Garaulet et al., 2006; Krotkiewski et al., 1983; Tchoukalova et al., 2008). Nevertheless, the
regional differences are negligible and there is a strong relationship in adipocyte size between different depots in the same individual
(Garaulet et al., 2006; Krotkiewski et al., 1983; Tchoukalova et al., 2008).
Transcriptional profiling and pathway analyses
In a subgroup of cohort 2 (before and after surgery, n = 16) and 3 (matched never-obese controls, n = 16), total RNAwas isolated from
intact sWAT and gene expression profiles generated using Affymetrix Human Gene 1.1 arrays (Affymetrix, Inc., Santa Clara, CA) as
described (Arner et al., 2015; Dahlman et al., 2015). Results were thereafter preprocessedwith the RobustMultichip Averagemethod.
Principal component analysis was performed using the FactomineR package. To identify differentially regulated genes comparing
subgroups, significance analysis of microarrays (SAM), with a false discovery rate (FDR) of 1%, was performed. Sets of genes (maxi-
mally the 200 most strongly regulated) displaying similar expression patterns were subjected to pathway analyses using the Web-
based Gene set analysis toolkit (WebGestalt) (Wang et al., 2013a). The top ten pathways were extracted from Gene ontology, Kyoto
Encyclopedia of Genes andGenomes andWikiGeneswith adjusted p values < 0.01 containingmore than three genes of interest were
considered relevant. For retrospective analysis of previously published microarray data based on human sWAT obtained from sub-
jects fed a lipid-enriched diet (Alligier et al., 2012), the 79 candidate genes identified in the current study were extrapolated and
analyzed for differential expression using SAM. RNA was extracted from human adipocyte progenitors treated with 10 ng/mL
TGFb3 for 24 hours and analyzed by the CLARIOM-S gene microarray (Affymetrix, Inc.). Data are based on two independent exper-
iments, each of which was run in triplicates.
RNA isolation, cDNA synthesis and real-time PCR
Total RNA was extracted from intact human or murine WAT, mature adipocytes, SVF as well as cell cultures as described previously
(Gao et al., 2014). The concentration, purity and quality were measured using Nanodrop 2000 (Thermo Fisher Scientific, Lafayette,
CO) and Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Total RNA was reverse transcribed with Omniscript RTCell Reports 25, 551–560.e1–e5, October 16, 2018 e3
(QIAGEN, Hilden, Germany) with random hexamer primers (Invitrogen, Carlsbad, CA) or iScript cDNA synthesis kits (Bio-Rad, Her-
cules, CA). Assessments of mRNA levels were performed using TaqMan assays (Applied Biosystems, Foster City, CA) and relative
expression was calculated with the comparative Ct-method, i.e., 2 DCt-target gene/2 DCt-reference gene. The following probes were used
(detailed in the Key Resources Table): 18S, CXCL12, FGF7, LRP10, OGN, PDGFD and TGFB3. Murine gene expression was as-
sessed using primers/probes targeting Tgfb3, Ckm, Adipoq, Ap2, Ccl2, Cidec, Irs1), Irs2, Plin, Pparg, Slc2a2, Slc2a4, Srebf1,
Tnfa, and normalized against 18S rRNA.
Protein secretion
Conditioned media was collected at day 1, 2, 3, 6, 8, 10 and 13 of human adipocyte differentiation and secreted levels of CXCL12
(DSA00, R&D Systems, Minneapolis, MN), FGF7 (DKG00, R&D Systems), OGN (SEC688Hu, Cloud-Clone Corp., Houston, TX),
PDGFD (E92919Hu, USCN Life Science, Wuhan, Peoples Republic of China) and TGFb3 (SEB949Hu, Cloud-Clone Corp.) were as-
sessed using Enzyme-Linked Immunosorbent Assay (ELISA). Tgfb3 secretion frommurine cells was assessed by ELISA according to
the manufacturer’s instructions (MyBiosource, MBS700631). Samples with weaker signals than the lowest point of the standard
curve were set to zero and all measurements were normalized to secretion per 24 hours.
Fluorescence Activated Cell Sorting and RNA expression analysis of WAT cell populations
The SVF and mature adipocytes were prepared from human sWAT obtained by liposuctions or plastic surgery as described (Gao
et al., 2014). Fluorescence activated cell sorting (FACS) of SVF was performed as described (Acosta et al., 2017). Progenitor cells
were sorted as CD45-/CD31-/CD34+, total macrophages as CD45+/CD14+/CD206+, M1 macrophages CD45+/CD14+/CD206+/
CD11c+, M2 macrophages CD45+/CD14+/CD206+/CD11c-, total T cells CD45+/CD3+, CD8 T cells CD45+/CD3+/CD8+ and
CD4 T cells CD45+/CD3+/CD4+. RNA Quality from total SVF, mature adipocytes, progenitor cells, leukocytes and macrophages
was assessed by Agilent Bioanalyzer 2100 (Agilent Technologies Inc., Santa Clara, CA), accepting RIN > 6.6. RNA was analyzed
onClariomDHuman assay (Thermo Fisher Scientific, Lafayette, CO) in accordancewith themanufacturer’s instructions as described
(Acosta et al., 2017). The single cell mRNA analysis in humanmacrophages and adipocyte progenitors is described in detail in (Acosta
et al., 2017).
Stimulation, differentiation and proliferation of adipocytes
hASC proliferation was estimated after addition of 1, 10 or 50/100 ng/mL recombinant human CXCL12 (P4566, Abnova Corp., Taipei
City, Taiwan), FGF7 (251-KG-010, R&D Systems), OGN (TP323948, OriGene Technologies Inc., Rockville, MD), and TGFb3 (243-B3-
002, R&D Systems), by staining with 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT, M2128, [Sigma-Aldrich,
St. Louis, MO]). Briefly, 4800 cells/cm2 were plated in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS (Thermo
Fisher Scientific) and allowed to adhere for 24 hours. Thereafter, they were washed twice with phosphate buffered saline (PBS)
and cultured in DMEM with or without the recombinant proteins detailed above. Approximately 72 hours later, cells were washed
twice with PBS and incubated for 60 minutes at 37 C in DMEM containing 0.3 mg/mL MTT. Supernatants were discarded and
MTT crystals were dissolved in 250 mL isopropanol. Finally, 100 mL of the lysate was transferred to 96-well plates and absorbance
was measured at 592 nm. For TGFb3, results were repeated in 3T3-L1 and murine primary adipose SVF cells using mouse recom-
binant protein (CYT-143, ProSpec, East Brunswick, NJ). For all experiments performed, cells cultured in DMEM supplemented with
10%FBSwas used as a positive control (results not shown) and all of the steps detailed above were carried out using phenol red-free
DMEM. For the TGFB3 RNAi and rescue experiments in human adipocyte precursors, proliferating cells were transfected with non-
silencing or TGFB3-specific siRNA oligonucleotides (Dharmacon, see Key Resources Table for details) using HiPerfect (QIAGEN)
according to the manufacturer’s instructions at day 0 and 1 after plating. Forty-eight hours after the first transfection, cells were incu-
bated with or without increasing concentrations of recombinant human TGFb3. Following an additional 48 hours, cell density was
determined by MTT as described above. Knockdown efficiency was determined by qPCR in parallel samples (i.e 96 hours after
the first transfection). The effect of recombinant murine Tgfb3 in Tgfb3/ (KO) MEFs was determined after 48 hours of incubation
by MTT. For assessments of effects on adipogenesis in human cells, adipocyte precursor cells were incubated with or without
TGFb3 for 48 hours. Following incubation, TGFb3 was removed and cells were incubated for 72 hours with basal medium in order
for the cells to undergo clonal expansion. This was followed by induction of differentiation as described above. After differentiation,
cells were fixed and stained with Oil red O and quantified as stated above.
5-ethynyl-20-deoxyuridine incorporation in vitro
MEFs collected from Tgfb3+/+ (Wt) and KO mice were plated in Corning CellBIND T75 flasks (1 million cells/flask). One day after
plating, the cells were incubated with theMEF culture media (described above) containing 10 mM5-ethynyl-20-deoxyuridine (EdU) for
24 hours, followed by an assessment of EdU positive cells using the Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry Assay Kit
(Life technologies, Carlsbad, CA) according to the manufacturer’s instructions. Analysis was performed on a LSRFortessa equipped
with 405 nm, 488 nm, 561 nm and 640 nm lasers and the Diva software (BD Biosciences).
For analyses in primary SVF fromWt and Hz mice, cells were plated in Corning CellBIND 96 well plates followed by incubation
with 10 mM EdU for 24 hours. Cells were then fixed in the plates using 4% paraformaldehyde for 15 minutes and stained using thee4 Cell Reports 25, 551–560.e1–e5, October 16, 2018
Click-iT Plus protocol. Incorporation of EdU and nuclear staining (Hoescht) were analyzed using a CellInsightCX5 High Content
Screening Platform at 10X magnification and expressed as % EdU positive cells. Effects on proliferation in SVF from Hz animals
were determined by the same EdU protocol after 24 hours of incubation with or without different concentrations of murine Tgfb3.
Assessment of lipid area
In vitro differentiated human adipocytes and MEFs were stained by Oil red O. Each treatment was done in triplicate. One picture per
well from a random spot were acquired at 4Xmagnification. TheOil redOpositive area in eachmicrophotograph was quantified using
ImageJ.
In vivo EdU incorporation
Themice were put on a high fat diet and given 5-ethynyl-20-deoxyuridine (EdU) in the drinking water at a concentration of 1 mg/mL (in
2% sucrose solution to offset taste aversion) from 4 weeks of age. EdU was removed from the drinking water after 1 week and the
mice continued on a high fat diet until 16 weeks of age at which point they were sacrificed. Mature adipocytes were isolated from the
sWAT and eWAT as described above followed by nuclear isolation and FACS sorting. In brief, packed adipocytes were lyzed and
homogenized in lysis buffer (10mMTris, 5nMMgCl2, 0.3M sucrose, 0.6%NP-40, and protease inhibitor cocktail (Roche)) by passing
through a syringe with a 20G needle 3 times. After spinning at 16,000g for 1 min, crude nuclei pellets were fixed, permeabilized and
stained with a Click-it EdU Alexa Fluor 488 assay according to the manufacturer’s instructions (Life technologies, C10337). Samples
were then rinsed in 1% BSA, resuspended in PBS containing 10 mg/mL 4,6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scien-
tific), and analyzed on a BD CytoFlex analyzer. Data analyses were performed using Flowlogic software (Miltenyi Biotec) and ex-
pressed as the percentage of DAPI positive events that were also EdU-Alexa 488 positive.
Metabolic evaluations in mice
Male animals were placed at 20C in a comprehensive laboratory animal monitoring system attached to a custom-built oxygen and
carbon dioxide monitoring system (PhenoMaster, TSE Systems, Germany). Airflow rates were 400 mL/min measurements of oxygen
concentration, with carbon dioxide concentration in room air and air leaving each cage were measured every 15 min. Energy expen-
diture (EE) was calculated from the amount of O2 consumed (called VO2) and the amount of CO2 produced (VCO2) using the equation:
EE (J) = 15.818VO2 + 5.176VCO2. The respiratory exchange rate (RER) was calculated with the ratio VCO2/VO2. The consumed
oxygen (VO2), activity, food and drink intake of each animal were calculated with these metabolic cages. Glucose tolerance tests
(GTTs) were performed as described (Medina-Gomez et al., 2007). In brief, after 16 hours of fasting glucose was administered intra-
peritoneally (1 g glucose/kg bodyweight). Blood glucose levels weremonitored using a glucosemeter (Boehringer) on 2.5 mL of blood
obtained from the tail vein; areas under curve (AUCs) were calculated and were expressed as mean ± SEM.
QUANTIFICATION AND STATISTICAL ANALYSIS
Values are mean ± SEM. Results were evaluated using paired/unpaired t test or analysis of variance (ANOVA). Fisher’s least signif-
icant difference post hoc tests were used. A statistical power calculation was made on available values for subcutaneous fat cell vol-
ume in 670 subjects investigated previously (Spalding et al., 2008). In two equally sized obese groups of subjects (10+10), we could
detect a 15% difference with alpha = 0.05 and 80% power by two-sided t test. Similarly, in two equally sized non-obese groups of
subjects (21+21), we had 90% power to detect a 15% difference with alpha = 0.05.
DATA AND MATERIALS AVAILABILITY
Human gene expression data are deposited in the National Center for Biotechnology Information Gene Expression Omnibus (https://
www.ncbi.nlm.nih.gov/geo/), accession number GSE59034.Cell Reports 25, 551–560.e1–e5, October 16, 2018 e5
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Figure S1 (related to Figure 1) Expression of identified growth factors, TGFβs and their receptors. A. Messenger RNA expression of 
the indicated genes in intact abdominal subcutaneous white adipose tissue (IT, black), isolated adipocytes (MA, white) and the stromal-
vascular fraction (SVF, grey). B. Secretion of indicated growth factors from human adipocyte precursor cells during in vitro 
adipogenesis. C. Human adipose-derived stem cells (hASCs) were incubated with 10 ng/mL TGFβ3 or control (Ctrl) medium for 24 
hours. Cells were lysed and RNA analyzed by gene microarray as shown in Figure 2. Heatmap representation of genes included in two of 
the top pathways, expression of individual genes in control (Ctrl) or TGFβ3-treated cells are shown. D-E. Messenger RNA expression of 
TGFB1-3 in cohort 2 and 3 determined by micro-array (panel D) and by RT-qPCR (panel E). F. TGFB3 mRNA expression determined by 
RT-qPCR in visceral WAT from obese (Ob) and non-obese (nOb) subjects. G-H. Gene expression of TGFβ receptors (G) and TGFβ 
ligands (H) determined by gene microarray in various cell fractions of human sWAT including: mature adipocytes and the following cells 
in the SVF: macrophages (M1, M2 and total), T-cells (CD4+, CD8+ and total) and adipocyte progenitors. The bars represent the mean 
array signal and error bars are standard error of the mean. I. T-distributed stochastic neighbor embedding (tSNE) plots of single cell gene 
expression in SVF cells isolated from human subcutaneous WAT. The cell populations identified are represented by the tSNE plot in the 
upper left panel. The macrophages can be subdivided into M1 (pink), M2 (blue) and mixed cells (orange) while adipocyte progenitors 
(green) cluster into a single population. The other panels show the expression of TGFB1-3 in the populations. TGFB3 expression is on 
average higher in progenitors than in macrophages and there is no distinct subpopulation within the progenitor fraction that is TGFB3-
specific. The tSNE plots are based on previously published data (Acosta et al., 2017). In panel A, D-E and G-H, ANOVA was used to 
evaluate the results and statistically significant differences (p<0.05) between fractions are indicated by connecting letters. In panel F 
**=p<0.01, using Student’s t-test. All error bars are S.D.
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Figure S2 (related to Figure 3). Gene expression in murine embryonic fibroblasts. A-I. Adipogenesis was induced in wildtype Tgfb3+/+ 
(WT) or Tgfb3-/- (KO) murine embryonic fibroblasts (MEFs) and the mRNA expression of adipogenic genes (A-C), Tgfβ1-3 (D-F) and 
Tgfβ3 receptors (G-I) were measured. The data points are mean expression from two independent experiments. J. Tgfβ3 KO MEFs were 
incubated with the indicated concentrations of recombinant murine Tgfβ3 and cell density was assessed by MTT staining (described in 
STAR Methods). K. Primary adipose SVF cells from Tgfb3+/- mice were incubated with the indicated concentrations of recombinant 
murine Tgfβ3. Proliferation was determined by EdU incorporation and expressed as % EdU positive cells as detailed in STAR Methods. 
Statistically significant differences (p<0.05) between conditions are indicated by connecting letters. All error bars are S.D.
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Figure S3 (related to Figure 4). Characterization of Tgfb3+/- mice. A-C. Wild type and Tgfb3 haploinsufficient male mice were fed 
chow (CD) or high-fat diet (HFD) for 11 weeks. Food intake (A), energy expenditure (B) and respiratory exchange ratio (C) was 
measured during a 42 h period in Tgfb3+/+ and Tgfb3+/- animals on CD or HFD during the final week before euthanizing the animals. D. 
The wet-weights of liver, skeletal muscle, pancreas, kidney, perininguinal (subcutaneous) white adipose tissue (sWAT), epigonadal 
(visceral) white adipose tissue (vWAT) and brown adipose tissue (BAT) were compared between the groups. In panel D ANOVA was 
used to evaluate the results and statistically significant differences (p<0.05) between groups are indicated by connecting letters. All 
error bars are S.D.
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Figure S4 (related to Figure 4). Further characterization of Tgfb3+/- mice. Wild type and Tgfb3 haploinsufficient male mice were fed 
chow or high-fat diet (HFD) for 11 weeks. A. Representative microphotographs of sWAT and vWAT from animals on CD. Scale bars are 
100 μm. B-C. For both depots mean adipocyte weight (panel B) and number (panel C) were assessed in the indicated WAT depots. D-E. 
Gene expression in sWAT (panel D) and vWAT (panel E) was determined in animals on CD. F-G. Gene expression in liver (panel F) and 
skeletal muscle (panel G) was determined by RT-qPCR in animals on CD or HFD as indicated. H-I. Insulin sensitivity were assessed by 
insulin tolerance test (ITT) in Tgfb3+/+ and Tgfb3+/- mice animals on CD or HFD (panel H). Area under the curve (AUC) was calculated 
(panel I). In panel H, ╪ denotes statistically significant difference between diets. J. Glucose tolerance tests were performed in Tgfb3+/+ 
and Tgfb3+/- mice fed CD. The AUCs are inserted. In panel C, D and E ***=p<0.001, **=p<0.01, *=p<0.05.,using Student’s t-test. In 
panel I and J, significant differences (p<0.05) are denoted by connecting letters. Error bars in panel D-G are S.D. Error bars in panel H and 
Tgfb3   CD+/+
Tgfb3+/- CD
Tgfb3   CD+/+
Tgfb3+/- CD
 J are S.E.M. 
Parameter Baseline Follow-up p-value Baseline Follow-up p-value Baseline Follow-up p-value
Age (yr) 40.8 ± 2.8 49.9 ± 3.7 0.000 39.3 ± 3.2 50.4 ± 3.3 0.000 36.8 ± 3.6 47.1 ± 3.6 0.000
BMI (kg/m
2
) 22.9 ± 0.6 22.9 ± 0.6 0.951 23.5 ± 0.6 24.6 ± 0.6 0.000 24.3 ± 1.6 28.8 ± 2.1 0.000
Waist (cm) 81.1 ± 2.7 82.0 ± 2.8 0.574 80.6 ± 2.4 89.2 ± 2.3 0.001 83.7 ± 4.2 96.5 ± 4.4 0.001
Hip (cm) 94.0 ± 2.2 95.6 ± 1.1 0.434 94.5 ± 2.7 98.2 ± 1.7 0.019 97.2 ± 3.3 106.4 ± 3.4 0.008
Waist-to-hip ratio 0.863 ± 0.024 0.857 ± 0.025 0.812 0.854 ± 0.018 0.907 ± 0.015 0.026 0.859 ± 0.021 0.904 ± 0.017 0.085
Body fat (%) 30.7 ± 1.1 30.9 ± 1.5 0.798 32.0 ± 1.9 34.4 ± 1.7 0.000 31.7 ± 3.3 40.6 ± 4.2 0.000
P-glucose (mmol/l) 4.9 ± 0.1 4.9 ± 0.1 0.820 4.9 ± 0.1 5.0 ± 0.1 0.575 5.0 ± 0.1 4.9 ± 0.1 0.782
P-insulin (mU/l) 6.1 ± 0.6 4.9 ± 0.8 0.287 5.5 ± 0.8 4.4 ± 0.7 0.111 7.6 ± 1.4 7.2 ± 1.4 1.000
Log10 HOMAIR 0.1 ± 0.1 -0.0 ± 0.1 0.210 0.0 ± 0.1 -0.1 ± 0.1 0.167 0.2 ± 0.1 0.1 ± 0.1 0.981
P-triglycerides (mmol/l) 0.8 ± 0.1 0.9 ± 0.1 0.194 0.9 ± 0.3 0.9 ± 0.2 0.963 1.0 ± 0.1 1.2 ± 0.3 0.238
Values are mean ± SEM
Table S1 (related to Figure 1). Clinical characteristics of Cohort 1. 
Tertile 1 - weight stable (n=9) Tertile 2 - intermediate group (n=9) Tertile 3 - weight gainers (n=9)
Abbreviations: BMI, body mass index; HOMAIR, homeostatic model assessment
Parameter Before (A)
p-value 
(A vs. C)
After (B)
p-value 
(A vs. B)
Controls       
(C)
p-value 
(B vs. C)
Early onset 
(n=11)
Late onset 
(n=10)
p-value
Early onset 
(n=11)
Late onset 
(n=10)
p-value
Birth weight (g) 3540.2 ± 177.3 3420.0 ± 238.9 0.697
Weight at 18 yr (kg) 81.3 ± 2.1 65 ± 2.7 0.000
BMI at 18 yr (kg/m
2
) 28.7 ± 0.8 22.6 ± 0.5 0.000
Age (yr) 46.1 ± 2.1 0.621 48.0 ± 2.1 0.000 47.7 ± 2.2 0.608 43.0 ± 3.1 49.6 ± 2.5 0.118 44.6 ± 3.0 51.6 ± 2.4 0.092
BMI (kg/m
2
) 41.1 ± 0.9 0.000 25.5 ± 0.6 0.000 25.1 ± 0.5 0.072 41.8 ± 1.4 40.4 ± 1.0 0.454 26.0 ± 0.5 24.9 ± 1.2 0.389
Waist (cm) 127.7 ± 1.9 0.000 87.8 ± 1.7 0.000 86.7 ± 1.5 0.432 126.8 ± 3.1 128.6 ± 2.3 0.654 87.4 ± 1.8 88.2 ± 3.2 0.818
Hip (cm) 128.9 ± 1.8 0.000 98.8 ± 1.5 0.000 99.6 ± 1.3 0.560 128.8 ± 2.5 129.1 ± 2.7 0.940 99.2 ± 1.5 98.3 ± 2.8 0.771
Waist-to-hip ratio 0.992 ± 0.012 0.000 0.891 ± 0.012 0.000 0.870 ± 0.012 0.054 0.985 ± 0.019 1.000 ± 0.014 0.528 0.887 ± 0.018 0.894 ± 0.017 0.795
Body fat (%) 52.8 ± 0.7 0.000 32.9 ± 1.5 0.000 34.6 ± 1.7 0.296 52.6 ± 1.0 53 ± 1.0 0.783 33.0 ± 1.0 32.8 ± 3.1 0.951
P-glucose (mmol/l) 5.6 ± 0.2 0.028 4.7 ± 0.1 0.000 5.1 ± 0.1 0.012 5.6 ± 0.3 5.6 ± 0.4 0.986 4.8 ± 0.2 4.6 ± 0.1 0.391
P-insulin (mU/l) 14.5 ± 2.0 0.000 4.2 ± 0.4 0.000 4.1 ± 0.4 0.921 13.0 ± 3.4 16.2 ± 2.1 0.449 3.9 ± 0.3 4.6 ± 0.7 0.406
Log10 HOMAIR 0.5 ± 0.1 0.000 -0.1 ± 0.0 0.000 -0.1 ± 0.0 0.704 0.4 ± 0.1 0.6 ± 0.1 0.178 -0.1 ± 0.0 -0.1 ± 0.1 0.887
P-triglycerides (mmol/l) 1.7 ± 0.2 0.001 1.0 ± 0.1 0.000 0.9 ± 0.1 0.687 1.6 ± 0.2 1.9 ± 0.3 0.397 0.9 ± 0.1 1.0 ± 0.1 0.482
Average adipocyte 
volume (pl)
957.3 ± 44.9 0.000 369.4 ± 29.5 0.000 485.1 ± 35.5 0.005 959.8 ± 66.7 954.2 ± 62.1 0.953 346.1 ± 26.4 397.9 ± 57.9 0.398
Adipocyte number 
(10
10
 cells)
7.1 ± 0.4 0.006 7.6 ± 0.4 0.161 5.7 ± 0.3 0.002 6.9 ± 0.5 7.3 ± 0.6 0.646 7.5 ± 0.5 7.8 ± 0.8 0.759
Abbreviations: BMI, body mass index; HOMAIR, homeostatic model assessment
Values are mean ± SEM
Before bariatric surgery After bariatric surgeryBariatric surgery (n=21)
Table S2 (related to Figure 1). Clinical characteristics of Cohort 2-3.
Never-obese (n=21)
Table S4 (related to Figure 1). Pathways perturbed in obesity, but normalized by weight loss.
Resource Pathway Pathway ID Adj. p-value
GO - biological process Small Molecule Metabolic Process GO:0044281 8.94E-06
GO - biological process Carboxylic Acid Catabolic Process GO:0046395 1.63E-05
GO - biological process Organic Acid Catabolic Process GO:0016054 1.63E-05
GO - biological process Single-Organism Catabolic Process GO:0044712 0.0002
GO - biological process Small Molecule Catabolic Process GO:0044282 0.0002
GO - biological process Fatty Acid Metabolic Process GO:0006631 0.0004
GO - biological process Carboxylic Acid Metabolic Process GO:0019752 0.0007
GO - biological process Oxoacid Metabolic Process GO:0043436 0.0013
GO - biological process Organic Acid Metabolic Process GO:0006082 0.0015
GO - biological process Water-Soluble Vitamin Metabolic Process GO:0006767 0.0026
GO - molecular function Oxidoreductase Activity, Acting On Ch-Oh Group Of Donors GO:0016614 0.0005
GO - molecular function Oxidoreductase Activity, Acting On The Ch-Oh Group Of Donors, Nad Or Nadp As AcceptorGO:0016616 0.001
GO - molecular function Alcohol Dehydrogenase (Nad) Activity GO:0004022 0.003
GO - molecular function Protein Dimerization Activity GO:0046983 0.0047
GO - molecular function Vitamin Binding GO:0019842 0.0047
GO - molecular function Anion Binding GO:0043168 0.0047
GO - molecular function Dipeptidase Activity GO:0016805 0.0047
GO - molecular function Cofactor Binding GO:0048037 0.0047
GO - molecular function Protein Homodimerization Activity GO:0042803 0.0056
GO - molecular function Amino Acid Binding GO:0016597 0.0063
KEGG pathway Insulin Signaling Pathway 4910 8.32E-05
KEGG pathway Metabolic Pathways 1100 8.32E-05
KEGG pathway Vitamin Digestion And Absorption 4977 0.0003
KEGG pathway Nitrogen Metabolism 910 0.0003
KEGG pathway Alanine, Aspartate And Glutamate Metabolism 250 0.0008
KEGG pathway Tyrosine Metabolism 350 0.0017
KEGG pathway Fatty Acid Metabolism 71 0.0017
KEGG pathway Arginine And Proline Metabolism 330 0.0035
KEGG pathway Glycine, Serine And Threonine Metabolism 260 0.006
KEGG pathway Propanoate Metabolism 640 0.006
Wikipathways pathway Adipogenesis WP236 0.0003
Wikipathways pathway Fatty Acid Biosynthesis WP357 0.0006
Wikipathways pathway Fatty Acid Omega Oxidation WP206 0.0008
Wikipathways pathway Ampk Signaling WP1403 0.0008
GO - biological process Immune System Process GO:0002376 2.74E-46
GO - biological process Immune Response GO:0006955 2.88E-45
GO - biological process Defense Response GO:0006952 6.93E-39
GO - biological process Inflammatory Response GO:0006954 1.61E-26
GO - biological process Response To Wounding GO:0009611 1.06E-24
GO - biological process Regulation Of Immune System Process GO:0002682 8.22E-23
GO - biological process Response To Stress GO:0006950 2.26E-22
GO - biological process Response To Stimulus GO:0050896 1.25E-21
GO - biological process Positive Regulation Of Immune System Process GO:0002684 3.45E-21
GO - biological process Regulation Of Immune Response GO:0050776 3.07E-19
GO - cellular component Cell Periphery GO:0071944 3.73E-18
GO - cellular component Plasma Membrane GO:0005886 3.73E-18
GO - cellular component Plasma Membrane Part GO:0044459 1.09E-12
GO - cellular component Membrane GO:0016020 2.11E-12
GO - cellular component Extracellular Space GO:0005615 3.62E-12
GO - cellular component Extracellular Region GO:0005576 2.80E-11
GO - cellular component Membrane Part GO:0044425 2.80E-11
GO - cellular component Extracellular Region Part GO:0044421 6.01E-11
GO - cellular component Intrinsic To Membrane GO:0031224 2.36E-10
GO - cellular component External Side Of Plasma Membrane GO:0009897 1.17E-09
GO - molecular function Igg Binding GO:0019864 2.17E-11
GO - molecular function Receptor Activity GO:0004872 6.97E-10
GO - molecular function Immunoglobulin Binding GO:0019865 1.62E-08
GO - molecular function Protein Complex Binding GO:0032403 5.93E-06
GO - molecular function Chemokine Activity GO:0008009 1.73E-05
GO - molecular function Receptor Binding GO:0005102 1.73E-05
GO - molecular function Chemokine Receptor Binding GO:0042379 5.09E-05
GO - molecular function Signaling Receptor Activity GO:0038023 0.0006
GO - molecular function Carbohydrate Derivative Binding GO:0097367 0.0006
GO - molecular function Signal Transducer Activity GO:0004871 0.0006
KEGG pathway Staphylococcus Aureus Infection 5150 3.45E-22
KEGG pathway Phagosome 4145 5.86E-15
KEGG pathway Osteoclast Differentiation 4380 5.86E-15
KEGG pathway Leishmaniasis 5140 7.72E-10
KEGG pathway Fc Gamma R-Mediated Phagocytosis 4666 8.98E-10
KEGG pathway Systemic Lupus Erythematosus 5322 2.58E-09
KEGG pathway Complement And Coagulation Cascades 4610 6.53E-09
KEGG pathway Hematopoietic Cell Lineage 4640 6.73E-08
KEGG pathway Chemokine Signaling Pathway 4062 1.78E-07
KEGG pathway Natural Killer Cell Mediated Cytotoxicity 4650 3.43E-07
Wikipathways pathway Complement And Coagulation Cascades WP558 6.98E-07
Wikipathways pathway Regulation Of Toll-Like Receptor Signaling Pathway WP1449 2.90E-05
Wikipathways pathway Focal Adhesion WP306 8.40E-05
Wikipathways pathway Complement Activation, Classical Pathway WP545 8.40E-05
Wikipathways pathway B Cell Receptor Signaling Pathway WP23 0.0004
Wikipathways pathway Toll-Like Receptor Signaling Pathway WP75 0.0004
Wikipathways pathway Inflammatory Response Pathway WP453 0.0007
Wikipathways pathway Osteoclast Signaling WP12 0.0024
Wikipathways pathway Il-3 Signaling Pathway WP286 0.0048
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